Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring)

Head-to-Head Comparison of 18-Gene-Based Clinical-Genomic Model and Oncotype DX 21-Gene Assay for Predicting Recurrence of Early-stage Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03772197

Enrollment

138

Registered

2018-12-11

Start date

2018-06-01

Completion date

2018-11-01

Last updated

2018-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Recurrence

Keywords

Breast cancer, Distant recurrence, NanoString, Gene-expression profiling, Prognosis, Locoreginal recurrence

Brief summary

A recurrence index for distant recurrence (RI-DR), an 18-gene-based clinical-genomic model, has been developed for early-stage breast cancer (EBC). In this study, Investigators compared the prognostic performance of the RI-DR with the Oncotype DX (ODx) recurrence score (RS) for any recurrence risk type.

Detailed description

With improved diagnosis, breast cancer can now be detected at early stages, thus improving survival rates. However, overtreatment is common; considering that the risk of recurrence is low, patients may suffer from side effects without receiving the full benefits of adjuvant therapies. To overcome the imprecision of prognosis based on clinicopathologic factors, genomic tests for breast cancer prognosis, such as the Oncotype DX® (ODx), MammaPrint®, and EndoPredict® assay kits, are frequently utilized. These multigene panels were development based on Caucasian populations, and may not suitable to Asian population due to the differences in the incidence and lifestyle of breast cancer patients from different ethic backgrounds. To fiil this gap, an 18-gene classifier (18-GC) based on the gene-expression profiling of Chinese breast cancer patients was developed In the current study, investigators combined clinical variables and genetic information to generate a clinical-genomic model: RI-DR, a recurrence index for distant recurrence (based on a genomic model and 6 clinical variables: age, tumor size, lymph node status, estrogen receptor status, lymphovascular invasion, tumor grading). By using tissues that have been tested with ODx, in this study, investigators evaluated the performance of the RI-DR model with that of the ODx assay in the prognosis assessment of a cohort of patients from Taiwan.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 75 Years

Inclusion criteria

1. Patients who have performed (Oncotype Dx) genetic testing methods before June 30, 2017. 2. Surgery (mastectomy or breast preservation) as the first treatment. 3. ER or PR IHC positive 4. HER2 negative 5. N0-N1 patient 6. Available with FFPE tumor tissue

Exclusion criteria

1. T3-T4 or N2-N3 2. With distant metastasis before surgery 3. Preoperative chemotherapy / radiotherapy 4. Insufficient FFPE tumor samples

Design outcomes

Primary

Measure	Time frame	Description
The locoregional recurrence (LRR) rate, within 5 years after surgery.	5 years	LRR risk calculated by 18-GC of breast cancer patients would be classified into high risk
The distant recurrence(DR) rate, within 5 years after surgery.	5 years	DR risk calculated by 18-GC of breast cancer patients would be classified into high risk

Countries

Taiwan

Outcome results